1. Executive Summary

2. Introduction
2.1 Post Operative Pain: An Overview
2.2 Analgesics: An Overview
2.3 Analgesics: Segments Overview
2.4 Long Acting Analgesics: An Overview

3. The US Market Analysis
3.1 The US Analgesic Market: An Analysis
3.1.1 The US Analgesic Market by Number of Procedures
3.1.2 The US Analgesic Market Procedures by Segments
3.1.3 The US Analgesic Market by Number of Orthopedic Procedures
3.1.4 The US Analgesic Market by Number of Soft Tissue Procedures
3.1.5 The US Analgesic Market by Number of Nerve Block Procedures
3.1.6 The US Analgesic Market by Generics and Other Brands Penetration
3.2 The US Long Acting Analgesic Market: An Analysis
3.2.1 The US Long Acting Analgesic Market by Penetration
3.2.2 The US Long Acting Analgesic Market by EXPAREL Penetration
3.2.3 The US Long Acting Analgesic Market by EXPAREL Sales
3.2.4 The US Long Acting Market by HTX-011 Penetration
3.2.5 The US Long Acting Analgesic Market by HTX-011 Sales

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Ageing Population
4.1.2 Disadvantages of Opioids
4.1.3 Upsurge in Use of Non Opioid Analgesics in Orthopedic Procedures
4.2 Challenges
4.2.1 Challenges in Commercialization of Exparel
4.3 Market Trends
4.3.1 Increase in Research and Development Expenses
4.3.2 Evolution of Multimodal Analgesics
4.3.3 Long Acting Analgesics in Pipeline
4.3.4 Low Penetration of Currently Used Local Analgesics

5. Competitive Landscape
5.1 The US Analgesic Market: Players Comparison

6. Company Profiles
6.1 Pacira Pharmaceutical, Inc. (EXPAREL)
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.2 Heron Therapeutics Inc. (HTX-011)
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy
6.3 Fresenius Group (NAROPIN)
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy

List of Figures
Figure 1: Analgesics Segments
Figure 2: The US Analgesic Market by Number of Procedures; 2016-2021 (million)
Figure 3: The US Analgesic Market Procedures by Segments; 2016 (Percentage,%)
Figure 4: The US Analgesic Market by Number of Orthopedic Procedures; 2016-2021(Million)
Figure 5: The US Analgesic Market by Number of Soft Tissue Procedures;2016 2021(Million)
Figure 6: The US Analgesic Market by Number of Nerve Block Procedures;2016-2021(Million)
Figure 7: The US Analgesic Market by Generic and Other Brands Penetration;2016-2021 (Percentage,%)
Figure 8: The US Long Acting Analgesic Market by Penetration; 2016-2021(Percentage,%)
Figure 9: The US Long Acting Analgesic Market by EXPAREL Penetration;2016-2021 (Percentage,%)
Figure 10: The US Long Acting Analgesic Market by EXPAREL Sales; 2012-2016 (US$ Million)
Figure 11: US Long Acting Analgesic Market by EXPAREL Sales; 2017-2021 (US$ Million)
Figure 12:The US Long Acting Analgesic Market by HTX-011 Penetration; 2016-2021 (Percentage,%)
Figure 13: US Long Acting Analgesic Market by HTX-011 Sales; 2019-2021 (US$ Million)
Figure 14: The US Ageing Population (65 Years and Above); 2012-2016 (Million)
Figure 15: Pacira Pharmaceutical Revenues; 2012-2016 (US$ Million)
Figure16:Pacira Pharmaceutical Research and Development Expenses; 2012-2016(US$ Million)
Figure17: Heron Therapeutics Research and Development Expenses;2012-2016(US$ Million)
Figure 18: Fresenius Sales; 2012-2016 (US$ Billion)
Figure 19: Fresenius Sales by Segments; 2016 (Percentage,%)

List of Tables
Table 1: Analgesics Segments: On the Basis of Type
Table 2: Analgesics Segments: On the Basis of Duration
Table 3: Analgesics Segments: On the Basis of Mode of Administration
Table 4: List of Procedure Making Use of Long Acting Procedures
Table 5: Long Acting Analgesics Under Development
Table 6:The US Analgesic Market Players Comparison